2023 Fall Clinical Virtual Grand Rounds
2023 Virtual Grand Rounds Session 11: September 13, 2023 - The Role of the IL17 Inhibitors in Targeted Management of Inflammatory Dermatologic Disorders
About
Fall Clinical Virtual Grand Rounds consist of regularly scheduled CME sessions on a variety of dermatological diseases and tools, delivered by the top experts in dermatology. Please join us for this week's session:
Wednesday, September 13, 2023
8 PM ET / 5 PM PT
The Role of the IL-17 Inhibitors Targeted in Management of Inflammatory Dermatologic Disorders
This activity is supported by an educational grant from UCB.
Availability
In order to ensure educational material is relevant, educational materials will expire after a certain time period. This course will be available for the following dates:
September 14, 2023
September 14, 2024
Learning Objectives
At the completion of this activity, participants should be better able to:
Explain the role of the IL-17 pathway in the pathophysiology of chronic inflammatory dermatologic disorders
Review data for IL-17 inhibitors for the management of inflammatory dermatologic disorders
Discuss strategies to educate patients about IL-17 inhibitors and incorporate these agents into clinical care
Intended Audience
Faculty
Gary Goldenberg, MD
Assistant Clinical Professor of Dermatology
Icahn School of Medicine at Mount Sinai
New York, NY
Joseph Merola, MD, MMSc
Professor and Chair
University of Texas Southwestern Medical Center
Dallas, TX
Jennifer Soung, MD
Director of Clinical Research
Southern California Dermatology
Clinical Faculty
Harbor University of California Los Angeles
Santa Ana, CA
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Institute for Continuing Healthcare Education and CMEsquared. The Institute is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation Statement
The Institute for Continuing Healthcare Education designates this live and enduring activity for a maximum of 1 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures & Disclaimers
Disclosures are as follows:
Grant/Research Support: Biofrontera
Consultant: CoolHealth, Cutera, Galderma, Regeneron, Sanofi, Scibase
Speakers’ Bureau or Honoraria: Regeneron Sanofi
Ownership Interest: Verrica
Grant/Research Support: J. F. Merola is a consultant and/or investigator for Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Abbvie, Dermavant, Eli Lilly, Incyte, Moonlake, Novartis, Janssen, UCB, Sanofi-Regeneron Consultant: J. F. Merola is a consultant and/or investigator for Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Abbvie, Dermavant, Eli Lilly, Incyte, Moonlake, Novartis, Janssen, UCB, Sanofi-Regeneron
Advisory Board/Consultant: Arcutis Biotechnology; Bristol Myers Squibb Company; Dermavant Sciences, Inc. Novartis, Abbvie, Lily, Pfizer, LEO Pharma, Regeneron, Sanofi, Amgen, Dermavant, Janssen, UCB
Shareholder: Pfizer
Grant/Research Support: AbbVie Inc.; Amgen Inc.; Arcutis Biotechnology; Castle Biosciences; Dermavant Sciences, Inc.; Janssen Pharmaceuticals, Inc.; KoBio Labs; Kyowa Kirin; LEO Pharma, Inc.; Lilly; Novartis; Pfizer Inc.; UCB Pharma, Inc
Speaker's Bureau: AbbVie Inc.; Amgen Inc.; Arcutis Biotechnology; Bristol Myers Squibb Company; LEO Pharma, Inc.; Lilly; Novartis; Ortho Dermatologics; Pfizer Inc.; Regeneron, Sanofi, Dermavant, Janssen
The Institute discloses that all relevant conflicts have been satisfactorily mitigated.